BioLife Solutions, Inc.
BLFS
$17.02
$0.221.31%
| Weiss Ratings | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.68 | |||
| Price History | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.88% | |||
| 30-Day Total Return | -6.60% | |||
| 60-Day Total Return | -9.27% | |||
| 90-Day Total Return | 24.88% | |||
| Year to Date Total Return | -0.75% | |||
| 1-Year Total Return | -18.04% | |||
| 2-Year Total Return | 15.01% | |||
| 3-Year Total Return | -52.19% | |||
| 5-Year Total Return | -2.10% | |||
| 52-Week High % Change | -31.43% | |||
| 52-Week Low % Change | 88.34% | |||
| Price | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $24.50 | |||
| 52-Week Low Price | $8.92 | |||
| 52-Week Low Price (Date) | Oct 30, 2023 | |||
| 52-Week High Price (Date) | Jun 06, 2023 | |||
| Valuation | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 718.46M | |||
| Enterprise Value | 709.45M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.52 | |||
| Earnings Per Share Growth | -53.68% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 4.96 | |||
| Price/Book (Q) | 2.12 | |||
| Enterprise Value/Revenue (TTM) | 5.25 | |||
| Price | $15.86 | |||
| Enterprise Value/EBITDA (TTM) | -16.62 | |||
| Enterprise Value/EBIT | -13.07 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 44.82M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 425 402 1400 | |||
| Address | 3303 Monte Villa Parkway Bothell, WA 98021 | |||
| Website | www.biolifesolutions.com | |||
| Country | United States | |||
| Year Founded | 1987 | |||
| Profitability | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -40.15% | |||
| Profit Margin | -46.36% | |||
| Management Effectiveness | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -8.33% | |||
| Return on Equity | -- | |||
| Income Statement | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 143.27M | |||
| Total Revenue (TTM) | 143.27M | |||
| Revenue Per Share | $3.20 | |||
| Gross Profit (TTM) | 46.75M | |||
| EBITDA (TTM) | -45.24M | |||
| EBIT (TTM) | -57.53M | |||
| Net Income (TTM) | -66.43M | |||
| Net Income Avl. to Common (TTM) | -66.43M | |||
| Total Revenue Growth (Q YOY) | -26.04% | |||
| Earnings Growth (Q YOY) | 72.79% | |||
| EPS Diluted (TTM) | -1.52 | |||
| EPS Diluted Growth (Q YOY) | 73.98% | |||
| Balance Sheet | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 51.70M | |||
| Cash Per Share (Q) | $1.15 | |||
| Total Current Assets (Q) | 120.60M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 337.66M | |||
| Current Ratio (Q) | 2.859 | |||
| Book Value Per Share (Q) | $7.48 | |||
| Total Assets (Q) | 412.71M | |||
| Total Current Liabilities (Q) | 42.18M | |||
| Total Debt (Q) | 42.69M | |||
| Total Liabilities (Q) | 75.05M | |||
| Total Common Equity (Q) | 337.66M | |||
| Cash Flow | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 17.84M | |||
| Cash from Financing (TTM) | 10.59M | |||
| Net Change in Cash (TTM) | 15.97M | |||
| Levered Free Cash Flow (TTM) | -5.10M | |||
| Cash from Operations (TTM) | -12.50M | |||
